NASDAQ:FBIO Fortress Biotech (FBIO) Stock Forecast, Price & News $0.34 +0.01 (+1.80%) (As of 08:58 AM ET) Add Compare Share Share Today's Range$0.34▼$0.3450-Day Range$0.33▼$0.6552-Week Range$0.31▼$1.16Volume284 shsAverage Volume618,611 shsMarket Capitalization$45.25 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Fortress Biotech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,397.0% Upside$5.00 Price TargetShort InterestHealthy0.77% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$117,500 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.92) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector304th out of 961 stocksPharmaceutical Preparations Industry138th out of 455 stocks 3.5 Analyst's Opinion Consensus RatingFortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Fortress Biotech has a forecasted upside of 1,397.0% from its current price of $0.33.Amount of Analyst CoverageFortress Biotech has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.77% of the float of Fortress Biotech has been sold short.Short Interest Ratio / Days to CoverFortress Biotech has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fortress Biotech has recently increased by 24.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFortress Biotech does not currently pay a dividend.Dividend GrowthFortress Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FBIO. Previous Next 1.5 News and Social Media Coverage News SentimentFortress Biotech has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Fortress Biotech this week, compared to 1 article on an average week.Search InterestOnly 17 people have searched for FBIO on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat Follows8 people have added Fortress Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fortress Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $117,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders26.90% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 18.15% of the stock of Fortress Biotech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Fortress Biotech are expected to grow in the coming year, from ($0.92) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fortress Biotech is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fortress Biotech is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFortress Biotech has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Fortress Biotech (NASDAQ:FBIO) StockFortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Read More FBIO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FBIO Stock News HeadlinesSeptember 18, 2023 | americanbankingnews.comFortress Biotech (NASDAQ:FBIO) Coverage Initiated by Analysts at StockNews.comSeptember 13, 2023 | seekingalpha.comFortress Biotech, Inc. 9.375% CUM RED PER PREF SER A USD25.00 goes ex-dividend tomorrowSeptember 21, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 7, 2023 | finance.yahoo.comMustang Bio to Participate in Upcoming September 2023 Investor ConferencesSeptember 7, 2023 | finance.yahoo.comFortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 6, 2023 | finance.yahoo.comJourney Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian NationsAugust 16, 2023 | finance.yahoo.comMustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell TherapyAugust 15, 2023 | finanznachrichten.deFortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsSeptember 21, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.August 14, 2023 | finance.yahoo.comFortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsAugust 14, 2023 | finance.yahoo.comMustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsAugust 8, 2023 | finance.yahoo.comJourney Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsAugust 3, 2023 | finance.yahoo.comMustang Bio to Participate in Two August 2023 Investor ConferencesAugust 1, 2023 | finance.yahoo.comAvenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical StudyAugust 1, 2023 | finance.yahoo.comInsiders Re-Evaluate Their US$3.4m Stock Purchase As Fortress Biotech Falls To US$77mJuly 27, 2023 | finance.yahoo.comAvenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)July 3, 2023 | finance.yahoo.comJourney Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023June 29, 2023 | finance.yahoo.comUrica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United StatesJune 28, 2023 | finance.yahoo.comCheckpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval DosingJune 13, 2023 | finance.yahoo.comJourney Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult SubjectsJune 8, 2023 | finance.yahoo.comFortress Biotech, Inc. (NASDAQ:FBIO) Looks Inexpensive But Perhaps Not Attractive EnoughMay 25, 2023 | msn.comFortress Biotech's Earnings: A PreviewMay 22, 2023 | finance.yahoo.comJourney Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsMay 19, 2023 | finance.yahoo.comJourney Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023May 16, 2023 | msn.comCantor Fitzgerald Maintains Fortress Biotech (FBIO) Overweight RecommendationMay 15, 2023 | msn.comFortress Biotech Non-GAAP EPS of -$0.06, revenue of $12.43MMay 15, 2023 | finance.yahoo.comFortress Biotech (FBIO) Reports Q1 Loss, Lags Revenue EstimatesSee More Headlines Receive FBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address FBIO Company Calendar Last Earnings8/14/2023Today9/21/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:FBIO CUSIP21976U10 CIK1429260 Webwww.fortressbiotech.com Phone(781) 652-4500Fax781-652-4545Employees187Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+1,397.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,570,000.00 Net Margins-152.63% Pretax Margin-357.79% Return on Equity-246.79% Return on Assets-36.07% Debt Debt-to-Equity Ratio4.62 Current Ratio0.99 Quick Ratio0.90 Sales & Book Value Annual Sales$75.74 million Price / Sales0.59 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book0.74Miscellaneous Outstanding Shares133,090,000Free Float97,287,000Market Cap$44.45 million OptionableOptionable Beta2.10 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Lindsay Allan Rosenwald (Age 68)Exec. Chairman, Pres & CEO Comp: $942.78kMr. Michael S. Weiss Esq. (Age 57)Vice Chairman & Exec. Vice Chairman of Strategic Devel. Comp: $167.92kMr. David Jin (Age 32)CFO & Head of Corp. Devel. Comp: $976.96kDr. George C. Avgerinos (Age 69)Sr. VP of Biologics Operations Comp: $386.49kMr. Samuel BerryGen. Counsel & Corp. Sec.Key CompetitorsBolt BiotherapeuticsNASDAQ:BOLTMolecular TemplatesNASDAQ:MTEMRegulus TherapeuticsNASDAQ:RGLSCatalyst BiosciencesNASDAQ:CBIOLantern PharmaNASDAQ:LTRNView All CompetitorsInsiders & InstitutionsLindsay A Md RosenwaldBought 10,000 shares on 8/17/2023Total: $117,500.00 ($11.75/share)Citadel Advisors LLCBought 800 shares on 8/15/2023Ownership: 0.000%BlackRock Inc.Sold 178,160 shares on 8/11/2023Ownership: 0.913%Geode Capital Management LLCBought 161,098 shares on 8/11/2023Ownership: 0.640%Renaissance Technologies LLCSold 24,073 shares on 8/11/2023Ownership: 0.170%View All Insider TransactionsView All Institutional Transactions FBIO Stock - Frequently Asked Questions Should I buy or sell Fortress Biotech stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FBIO shares. View FBIO analyst ratings or view top-rated stocks. What is Fortress Biotech's stock price forecast for 2023? 3 brokers have issued 1-year price targets for Fortress Biotech's stock. Their FBIO share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 1,397.0% from the stock's current price. View analysts price targets for FBIO or view top-rated stocks among Wall Street analysts. How have FBIO shares performed in 2023? Fortress Biotech's stock was trading at $0.6550 at the start of the year. Since then, FBIO shares have decreased by 49.0% and is now trading at $0.3340. View the best growth stocks for 2023 here. Are investors shorting Fortress Biotech? Fortress Biotech saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 710,900 shares, an increase of 24.1% from the August 15th total of 572,800 shares. Based on an average daily trading volume, of 621,500 shares, the short-interest ratio is presently 1.1 days. Approximately 0.8% of the shares of the company are short sold. View Fortress Biotech's Short Interest. When is Fortress Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our FBIO earnings forecast. How were Fortress Biotech's earnings last quarter? Fortress Biotech, Inc. (NASDAQ:FBIO) announced its quarterly earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.02. The biopharmaceutical company earned $17.39 million during the quarter, compared to analyst estimates of $13.28 million. Fortress Biotech had a negative trailing twelve-month return on equity of 246.79% and a negative net margin of 152.63%. What other stocks do shareholders of Fortress Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX). What is Fortress Biotech's stock symbol? Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO." Who are Fortress Biotech's major shareholders? Fortress Biotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.91%), Acadian Asset Management LLC (0.80%), Geode Capital Management LLC (0.64%), 1900 Wealth Management LLC (0.30%), Renaissance Technologies LLC (0.17%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Eric K Rowinsky, Lindsay A Md Rosenwald and Robyn Hunter. View institutional ownership trends. How do I buy shares of Fortress Biotech? Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Fortress Biotech's stock price today? One share of FBIO stock can currently be purchased for approximately $0.33. How much money does Fortress Biotech make? Fortress Biotech (NASDAQ:FBIO) has a market capitalization of $44.45 million and generates $75.74 million in revenue each year. The biopharmaceutical company earns $-86,570,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. How many employees does Fortress Biotech have? The company employs 187 workers across the globe. How can I contact Fortress Biotech? Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.fortressbiotech.com. The biopharmaceutical company can be reached via phone at (781) 652-4500, via email at ir@fortressbiotech.com, or via fax at 781-652-4545. This page (NASDAQ:FBIO) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.